Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
APremilast After FumaRic Acid Ester Treatment
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 687
- Registration Number
- NCT02954081
- Locations
- 🇩🇪
Site, Hamburg, Germany
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Drug: Immediate Release (IR) FormulationDrug: Gastro-Retentive (GR) Formulation
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT02939183
- Locations
- 🇪🇸
Research Site, Pamplona, Navarra, Spain
Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: InfliximabBiological: ABP 710
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 558
- Registration Number
- NCT02937701
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Recruiting
- Conditions
- Herpetic InfectionMelanoma
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 300
- Registration Number
- NCT02910557
- Locations
- 🇺🇸
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸Corazon United States of America, LLC doing business as Life Clinical Trials, Coral Springs, Florida, United States
🇺🇸Mercy Medical Center, Baltimore, Maryland, United States
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT02910063
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Study to Evaluate the Safety of Repatha® in Pregnancy
Terminated
- Conditions
- HypercholesterolaemiaPregnancy
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4
- Registration Number
- NCT02906124
- Locations
- 🇬🇧
Research Site, Stevenage, United Kingdom
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
Phase 3
Completed
- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 467
- Registration Number
- NCT02833844
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
Completed
- Conditions
- HypercholesterolemiaFamilial Hypercholesterolemia
- Interventions
- Other: No intervention
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6000
- Registration Number
- NCT02808403
- Locations
- 🇯🇵
Research Site, Kofu city, Yamanashi Prefecture, Japan
Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT02802735
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Phase 3
Completed
- Conditions
- Friedreich's Ataxia
- Interventions
- Drug: interferon γ-1b
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 38
- Registration Number
- NCT02797080
- Locations
- 🇺🇸
University of California, Los Angeles Neurology Clinic, Los Angeles, California, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸University of Florida Clinical Research Center, Gainesville, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath